Taro Pharmaceutical Indus... (TARO)
Taro Pharmaceutical Industries Statistics
Share Statistics
Taro Pharmaceutical Industries has 37.58M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 37.58M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 12.42% |
| Shares Floating | 8.09M |
| Failed to Deliver (FTD) Shares | 14.57K |
| FTD / Avg. Volume | 44.26% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 29.47 and the forward PE ratio is null. Taro Pharmaceutical Industries's PEG ratio is 0.27.
| PE Ratio | 29.47 |
| Forward PE | n/a |
| PS Ratio | 2.52 |
| Forward PS | n/a |
| PB Ratio | 0.89 |
| P/FCF Ratio | 20.3 |
| PEG Ratio | 0.27 |
Enterprise Valuation
Taro Pharmaceutical Industries has an Enterprise Value (EV) of 1.22B.
| EV / Sales | 1.95 |
| EV / EBITDA | 31.88 |
| EV / EBIT | 9.25 |
| EV / FCF | 15.66 |
Financial Position
The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.
| Current Ratio | 3.61 |
| Quick Ratio | 3.04 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 3% and Return on Invested Capital is 0.78%.
| Return on Equity | 3% |
| Return on Assets | 2.49% |
| Return on Invested Capital | 0.78% |
| Revenue Per Employee | $404.88K |
| Profits Per Employee | $34.66K |
| Employee Count | 1,554 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 1.58 |
Taxes
| Income Tax | 28.8M |
| Effective Tax Rate | 34.84% |
Stock Price Statistics
The stock price has increased by 1.85% in the last 52 weeks. The beta is 0.56, so Taro Pharmaceutical Industries's price volatility has been higher than the market average.
| Beta | 0.56 |
| 52-Week Price Change | 1.85% |
| 50-Day Moving Average | 42.5 |
| 200-Day Moving Average | 40.2 |
| Relative Strength Index (RSI) | 64.79 |
| Average Volume (20 Days) | 32.93K |
Income Statement
In the last 12 months, Taro Pharmaceutical Industries had revenue of 629.18M and earned 53.87M in profits. Earnings per share was 1.43.
| Revenue | 629.18M |
| Gross Profit | 304.98M |
| Operating Income | 21.51M |
| Net Income | 53.87M |
| EBITDA | 38.4M |
| EBIT | n/a |
| Earnings Per Share (EPS) | 1.43 |
Balance Sheet
The company has 362.91M in cash and 0 in debt, giving a net cash position of 362.91M.
| Cash & Cash Equivalents | 362.91M |
| Total Debt | 0 |
| Net Cash | 362.91M |
| Retained Earnings | 0 |
| Total Assets | 2.16B |
| Working Capital | 942.3M |
Cash Flow
In the last 12 months, operating cash flow was 132.39M and capital expenditures -54.22M, giving a free cash flow of 78.17M.
| Operating Cash Flow | 132.39M |
| Capital Expenditures | -54.22M |
| Free Cash Flow | 78.17M |
| FCF Per Share | 2.08 |
Margins
Gross margin is 48.47%, with operating and profit margins of 3.42% and 8.56%.
| Gross Margin | 48.47% |
| Operating Margin | 3.42% |
| Pretax Margin | 13.14% |
| Profit Margin | 8.56% |
| EBITDA Margin | 6.1% |
| EBIT Margin | 3.42% |
| FCF Margin | 12.42% |
Dividends & Yields
TARO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 3.39% |
| FCF Yield | 4.92% |
Analyst Forecast
Currently there are no analyst rating for TARO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 27, 2001. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 27, 2001 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 3.49 |
| Piotroski F-Score | 7 |